Calithera Biosciences, Inc. (CALA - Free Report) is a clinical-stage pharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CALA’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Calithera Biosciences could be a solid choice for investors.
Current Quarter Estimates for CALA
In the past 30 days, Calithera Biosciences’ trend has been pretty favorable, with estimates narrowing from a loss of 29 cents a share 30 days ago, to a loss of 25 cents today, a move of 13.8%.
Current Year Estimates for CALA
Meanwhile, Calithera Biosciences current year figures are also looking quite promising. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 96 cents per share 30 days ago to a loss of 88 cents per share today, an increase of 8.3%.
Calithera Biosciences, Inc. Price and Consensus
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Calithera Biosciences, Inc. (CALA - Free Report) is a clinical-stage pharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CALA’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Calithera Biosciences could be a solid choice for investors.
Current Quarter Estimates for CALA
In the past 30 days, Calithera Biosciences’ trend has been pretty favorable, with estimates narrowing from a loss of 29 cents a share 30 days ago, to a loss of 25 cents today, a move of 13.8%.
Current Year Estimates for CALA
Meanwhile, Calithera Biosciences current year figures are also looking quite promising. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 96 cents per share 30 days ago to a loss of 88 cents per share today, an increase of 8.3%.
Calithera Biosciences, Inc. Price and Consensus
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on CALA - FREE